잠시만 기다려 주세요. 로딩중입니다.

Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series

Infection & Chemotherapy 2020년 52권 3호 p.369 ~ 380
이충만, 안미영, Byeon Kyeong-min, 최재필, Hahm Cho-Rom, 김현목, 김수현, 김태훈, 오정균, 오동현,
소속 상세정보
이충만 ( Lee Choong-Man ) - Seoul Medical Center Department of Internal Medicine
안미영 ( Ahn Mi-Young ) - Seoul Medical Center Department of Internal Medicine
 ( Byeon Kyeong-min ) - Seoul Medical Center Department of Internal Medicine
최재필 ( Choi Jae-Phil ) - Seoul Medical Center Department of Internal Medicine
 ( Hahm Cho-Rom ) - Seoul Medical Center Department of Internal Medicine
김현목 ( Kim Hyeon-Mok ) - Seoul Medical Center Department of Internal Medicine
김수현 ( Kim Su-Hyun ) - Seoul Medical Center Department of Internal Medicine
김태훈 ( Kim Tae-Hoon ) - Seoul Medical Center Department of Internal Medicine
오정균 ( Oh Jung-Kyun ) - Seoul Medical Center Department of Hospital Medicine
오동현 ( Oh Dong-Hyun ) - Seoul Medical Center Department of Internal Medicine

Abstract


Background: A novel antiviral agent, remdesivir (RDV), is a promising candidate treatment for coronavirus disease 2019 (COVID-19) in the absence of any proven therapy.

Materials and Methods: This retrospective case series included 10 patients with a clinically and laboratory confirmed diagnosis of severe COVID-19 pneumonia who had received RDV for 5 days (n = 5) or 10 days (n = 5) in the Phase III clinical trial of RDV (GS-US-540-5773) conducted by Gilead Sciences. The clinical and laboratory data for these patients were extracted.

Results: One patient in the 10-day group received RDV for only 5 days because of nausea and elevated liver transaminases. No patient had respiratory comorbidity. Seven patients had bilateral lesions and three had unilateral lesions on imaging. All patients had received other medications for COVID-19, including lopinavir/ritonavir and hydroxychloroquine, before administration of RDV. Five patients required supplemental oxygen and one required mechanical ventilation. All patients showed clinical and laboratory evidence of improvement. Half of the patients developed elevated liver transaminases and three had nausea. There were no adverse events exceeding grade 2.

Conclusion: Our experience indicates that RDV could be a therapeutic option for COVID-19. A well-designed randomized controlled clinical trial is now needed to confirm the efficacy of RDV in patients with COVID-19.

키워드

Coronavirus disease 2019; COVID-19; Severe acute respiratory syndrome coronavirus 2; Remdesivir; Pneumonia

원문 및 링크아웃 정보

등재저널 정보